All the latest Form happenings. Want to stay in the loop? Subscribe Now
AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer’s disease.
Partnership leverages AI-powered genome design to optimize AAV constructs, accelerate lead candidate selection, and improve drug substance manufacturability for rare and ultra-rare neuromuscular diseases
She succeeds co-founders Andrew Busey, CEO, and President and COO Kent Wakeford, who have led the Texas-based biotech since its 2022 spinout from Colossal Biosciences.
Proven technology driven biotech leader to accelerate company's next phase of AI-powered growth in genetic medicine and genome engineering
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.
.webp)
